Dual Antiplatelet Treatment up to 72 Hours after Ischemic Stroke
- PMID: 38157499
- DOI: 10.1056/NEJMoa2309137
Dual Antiplatelet Treatment up to 72 Hours after Ischemic Stroke
Abstract
Background: Dual antiplatelet treatment has been shown to lower the risk of recurrent stroke as compared with aspirin alone when treatment is initiated early (≤24 hours) after an acute mild stroke. The effect of clopidogrel plus aspirin as compared with aspirin alone administered within 72 hours after the onset of acute cerebral ischemia from atherosclerosis has not been well studied.
Methods: In 222 hospitals in China, we conducted a double-blind, randomized, placebo-controlled, two-by-two factorial trial involving patients with mild ischemic stroke or high-risk transient ischemic attack (TIA) of presumed atherosclerotic cause who had not undergone thrombolysis or thrombectomy. Patients were randomly assigned, in a 1:1 ratio, within 72 hours after symptom onset to receive clopidogrel (300 mg on day 1 and 75 mg daily on days 2 to 90) plus aspirin (100 to 300 mg on day 1 and 100 mg daily on days 2 to 21) or matching clopidogrel placebo plus aspirin (100 to 300 mg on day 1 and 100 mg daily on days 2 to 90). There was no interaction between this component of the factorial trial design and a second part that compared immediate with delayed statin treatment (not reported here). The primary efficacy outcome was new stroke, and the primary safety outcome was moderate-to-severe bleeding - both assessed within 90 days.
Results: A total of 6100 patients were enrolled, with 3050 assigned to each trial group. TIA was the qualifying event for enrollment in 13.1% of the patients. A total of 12.8% of the patients were assigned to a treatment group no more than 24 hours after stroke onset, and 87.2% were assigned after 24 hours and no more than 72 hours after stroke onset. A new stroke occurred in 222 patients (7.3%) in the clopidogrel-aspirin group and in 279 (9.2%) in the aspirin group (hazard ratio, 0.79; 95% confidence interval [CI], 0.66 to 0.94; P = 0.008). Moderate-to-severe bleeding occurred in 27 patients (0.9%) in the clopidogrel-aspirin group and in 13 (0.4%) in the aspirin group (hazard ratio, 2.08; 95% CI, 1.07 to 4.04; P = 0.03).
Conclusions: Among patients with mild ischemic stroke or high-risk TIA of presumed atherosclerotic cause, combined clopidogrel-aspirin therapy initiated within 72 hours after stroke onset led to a lower risk of new stroke at 90 days than aspirin therapy alone but was associated with a low but higher risk of moderate-to-severe bleeding. (Funded by the National Natural Science Foundation of China and others; INSPIRES ClinicalTrials.gov number, NCT03635749.).
Copyright © 2023 Massachusetts Medical Society.
Similar articles
-
Clopidogrel and Aspirin Initiated Between 24 to 72 Hours for Mild Ischemic Stroke: A Subgroup Analysis of the INSPIRES Randomized Clinical Trial.JAMA Netw Open. 2024 Sep 3;7(9):e2431938. doi: 10.1001/jamanetworkopen.2024.31938. JAMA Netw Open. 2024. PMID: 39240565 Free PMC article. Clinical Trial.
-
Duration of Benefit and Risk of Dual Antiplatelet Therapy up to 72 Hours After Mild Ischemic Stroke and Transient Ischemic Attack.Neurology. 2024 Oct 8;103(7):e209845. doi: 10.1212/WNL.0000000000209845. Epub 2024 Sep 13. Neurology. 2024. PMID: 39270151 Clinical Trial.
-
Rationale and design of a randomised double-blind 2×2 factorial trial comparing the effect of a 3-month intensive statin and antiplatelet therapy for patients with acute mild ischaemic stroke or high-risk TIA with intracranial or extracranial atherosclerosis (INSPIRES).Stroke Vasc Neurol. 2023 Jun;8(3):249-258. doi: 10.1136/svn-2022-002084. Epub 2023 Jan 27. Stroke Vasc Neurol. 2023. PMID: 36707080 Free PMC article. Clinical Trial.
-
Ticagrelor versus clopidogrel in dual antiplatelet therapy after minor stroke or transient ischemic attack: an updated network meta-analysis.J Neurol. 2024 Jun;271(6):3030-3038. doi: 10.1007/s00415-024-12330-3. Epub 2024 Apr 5. J Neurol. 2024. PMID: 38580815 Review.
-
Efficacy and safety of clopidogrel and/or aspirin for ischemic stroke/transient ischemic attack: An overview of systematic reviews and meta-analysis.Medicine (Baltimore). 2021 Dec 17;100(50):e27804. doi: 10.1097/MD.0000000000027804. Medicine (Baltimore). 2021. PMID: 34918630 Free PMC article. Review.
Cited by
-
Uptake of Dual Antiplatelet Therapy After High-Risk Transient Ischemic Attack at a University Hospital.Neurohospitalist. 2024 Oct 9:19418744241289625. doi: 10.1177/19418744241289625. Online ahead of print. Neurohospitalist. 2024. PMID: 39544269 Free PMC article.
-
Possible clinical and radiological predictors of haemorrhagic transformation in acute stroke patients undergoing dual antiplatelet therapy: a clinical study.Ther Adv Neurol Disord. 2024 Oct 21;17:17562864241289735. doi: 10.1177/17562864241289735. eCollection 2024. Ther Adv Neurol Disord. 2024. PMID: 39445085 Free PMC article.
-
Early Neurological Deterioration and Time to Start Dual Antiplatelet Therapy in Patients With Acute Mild-to-Moderate Ischemic Stroke: A Pre-Specified Post Hoc Analysis of the ATAMIS Trial.J Stroke. 2024 Sep;26(3):403-414. doi: 10.5853/jos.2024.02250. Epub 2024 Sep 30. J Stroke. 2024. PMID: 39396833 Free PMC article.
-
Clopidogrel and Aspirin Initiated Between 24 to 72 Hours for Mild Ischemic Stroke: A Subgroup Analysis of the INSPIRES Randomized Clinical Trial.JAMA Netw Open. 2024 Sep 3;7(9):e2431938. doi: 10.1001/jamanetworkopen.2024.31938. JAMA Netw Open. 2024. PMID: 39240565 Free PMC article. Clinical Trial.
-
Beyond RCTs: Short-term dual antiplatelet therapy in secondary prevention of ischemic stroke and transient ischemic attack.Eur Stroke J. 2024 Dec;9(4):989-999. doi: 10.1177/23969873241255250. Epub 2024 Jun 13. Eur Stroke J. 2024. PMID: 38869034 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical